Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.

Breast cancer research and treatment - 1 Apr 2010

Dunlap Jennifer, Le Claudia, Shukla Arielle, Patterson Janice, Presnell Ajia, Heinrich Michael C, Corless Christopher L, Troxell Megan L

Abstract excerpt

Mutationally activated protein kinases are appealing therapeutic targets in breast carcinoma. Mutations in phosphatidylinositol-3-kinase (PI3KCA) have been described in 8-40% of invasive breast carcinomas, and AKT1 mutations have been characterized in 1-8% of breast carcinomas. However, there is little data on these mutations in breast precursor lesions. To further delineate the molecular evolution of breast...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Ductal, Breast
Share to Carcinoma, Intraductal, Noninfiltrating

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to In Situ Hybridization, Fluorescence

Share to Lasers

Share to Microdissection

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins c-akt

Source

Identifiers

PMID: 19418217
DOI: 10.1007/s10549-009-0406-1

Genes

AKT1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.PMID 19418217Read ↗

PIK3CA mutations in in situ and invasive breast carcinomas.Semantic proximity Read ↗

PIK3CA/AKT1 Mutations in Breast Carcinoma: a Comprehensive Review of Experimental and Clinical StudiesSemantic proximity Read ↗

PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.Semantic proximity Read ↗

Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions.Semantic proximity Read ↗

Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.Semantic proximity Read ↗

Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions.Semantic proximity Read ↗

PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.Semantic proximity Read ↗

Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.Semantic proximity Read ↗

High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.Semantic proximity Read ↗

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.Semantic proximity Read ↗

PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.Semantic proximity Read ↗

PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.